Literature DB >> 22704737

Multiplexing immunoassays for cytokine detection in the serum of patients with rheumatoid arthritis: lack of sensitivity and interference by rheumatoid factor.

Sarah M Churchman1, Janina Geiler, Rekha Parmar, Elizabeth A Horner, Leigh D Church, Paul Emery, Maya H Buch, Michael F McDermott, Frederique Ponchel.   

Abstract

OBJECTIVES: Accurately measuring cytokines in clinical material remains an important challenge in the development of biomarkers. Enzyme-linked immunoabsorbent assays (ELISAs) are considered 'gold standard'; however, their use is limited by the relatively large sample volume required for multiple analyte testing. Several alternatives (including membrane or bead-ELISA) have been developed particularly to enable multiplexing. Concerns were raised regarding their use in rheumatology due to interference by heterophilic antibodies, notably rheumatoid factor (RF). In this report, we compared several multiplex assays using serum from rheumatoid arthritis (RA) patients with respect to the presence of residual RF following attempted removal employing commonly used procedures.
METHODS: Healthy control and RF-positive/negative RA sera were used to compare 4 multiplex assays with ELISA: bead-based 'Luminex' immunoassay, cytometric bead assays (CBAs), membrane-based and Mosaic™ ELISAs. Sera were tested following Ig blockade (mixed species serum) or removal (using PEG6000 or sepharose-L).
RESULTS: Ig removal was only partially efficient and residual RF was detected in most sera. RF had no impact on cytokine measurement by ELISA. In single and multiplex Luminex, cytokine levels associated with false positive results correlated directly with RF titres. Following Ig-blockade/removal, these relationship remained suggesting false positivity was still associated with the presence of residual RF. Conversely, detection of cytokines in multiplex membrane-based or Mosaic- ELISA were not affected by the presence of RF; however, levels of cytokines readily detected by ELISA were often below the detection threshold of these assays. CBA assays were also low on sensitivity but unaffected by RF.
CONCLUSIONS: False positivity, due to the presence of heterophilic antibodies, mainly affected Luminex assays. Other assays however remained limited in their sensitivity. Multiplexing of cytokine measurement remains a challenge, particularly in rheumatological pathologies, until assays of adequate sensitivity are developed. ELISA remains the gold standard.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22704737

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  16 in total

1.  The ratios of pro-inflammatory to anti-inflammatory cytokines in the serum of chronic periodontitis patients with and without type 2 diabetes and/or smoking habit.

Authors:  Tamires Szeremeske Miranda; Sílvia Lacerda Heluy; Daniele Ferreira Cruz; Hélio Doyle Pereira da Silva; Magda Feres; Luciene Cristina Figueiredo; Poliana Mendes Duarte
Journal:  Clin Oral Investig       Date:  2018-05-08       Impact factor: 3.573

2.  Comparable long-term outcomes between DAS28-ESR remission criteria and ACR/EULAR definitions in patients with established rheumatoid arthritis.

Authors:  Julio Ramírez; José Inciarte-Mundo; Andrea Cuervo; Raquel Celis; Virginia Ruiz-Esquide; Raul Castellanos-Moreira; Andrés Ponce; José A Gómez-Puerta; Raimon Sanmartí; Juan D Cañete
Journal:  Clin Rheumatol       Date:  2021-01-27       Impact factor: 2.980

3.  Measurement of Circulating Cytokines and Immune-Activation Markers by Multiplex Technology in the Clinical Setting: What Are We Really Measuring?

Authors:  Najib Aziz
Journal:  For Immunopathol Dis Therap       Date:  2015

4.  Differences in synovial fluid cytokine levels but not in synovial tissue cell infiltrate between anti-citrullinated peptide/protein antibody-positive and -negative rheumatoid arthritis patients.

Authors:  José A Gómez-Puerta; Raquel Celis; M Victoria Hernández; Virginia Ruiz-Esquide; Julio Ramírez; Isabel Haro; Juan D Cañete; Raimon Sanmartí
Journal:  Arthritis Res Ther       Date:  2013-11-07       Impact factor: 5.156

5.  Patients with rheumatoid arthritis in clinical remission and ultrasound-defined active synovitis exhibit higher disease activity and increased serum levels of angiogenic biomarkers.

Authors:  Julio Ramírez; Virginia Ruíz-Esquide; Isaac Pomés; Raquel Celis; Andrea Cuervo; Ma Victoria Hernández; Jaume Pomés; José L Pablos; Raimon Sanmartí; Juan D Cañete
Journal:  Arthritis Res Ther       Date:  2014-01-08       Impact factor: 5.156

6.  A simple set of validation steps identifies and removes false results in a sandwich enzyme-linked immunosorbent assay caused by anti-animal IgG antibodies in plasma from arthritis patients.

Authors:  Tue W Kragstrup; Thomas Vorup-Jensen; Bent Deleuran; Malene Hvid
Journal:  Springerplus       Date:  2013-06-15

7.  Immune response profiling in early rheumatoid arthritis: discovery of a novel interaction of treatment response with viral immunity.

Authors:  John M Davis; Keith L Knutson; Michael A Strausbauch; Abigail B Green; Cynthia S Crowson; Terry M Therneau; Eric L Matteson; Sherine E Gabriel
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

8.  ACPA fine-specificity profiles in early rheumatoid arthritis patients do not correlate with clinical features at baseline or with disease progression.

Authors:  Joyce J B C van Beers; Annemiek Willemze; Jeroen J Jansen; Gerard H M Engbers; Martin Salden; Jos Raats; Jan W Drijfhout; Annette H M van der Helm-van Mil; Rene E M Toes; Ger J M Pruijn
Journal:  Arthritis Res Ther       Date:  2013-10-01       Impact factor: 5.156

Review 9.  Cytokines as biomarkers in rheumatoid arthritis.

Authors:  Agata Burska; Marjorie Boissinot; Frederique Ponchel
Journal:  Mediators Inflamm       Date:  2014-03-09       Impact factor: 4.711

10.  Negative interference in serum HBsAg ELISA from rheumatoid factors.

Authors:  Lei Xu; Zhen Yu; Wen Fan; Xueping Wang; Mingshui Xie; Yiting Xu; Lihua Hu; Yirong Li
Journal:  PLoS One       Date:  2013-11-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.